Results showed that although transfection of miR-181a mimic led to the phosphorylation of Akt–mTOR, MK-2206 treatment blocked miR-181a overexpression-induced activation of Akt–mTOR signaling in BC cells (Fig. 8B). Here, MTOR is linked to breast cancer.